RESUMEN
Plasmodium vivax is a major challenge for malaria control due to its wide geographic distribution, high frequency of submicroscopic infections, and ability to induce relapses due to the latent forms present in the liver (hypnozoites). Deepening our knowledge of parasite biology and its molecular components is key to develop new tools for malaria control and elimination. This study aims to investigate and characterize a P. vivax protein (PvVir14) for its role in parasite biology and its interactions with the immune system. We collected sera or plasma from P.vivax-infected subjects in Brazil (n = 121) and Cambodia (n = 55), and from P. falciparum-infected subjects in Mali (n = 28), to assess antibody recognition of PvVir14. Circulating antibodies against PvVir14 appeared in 61% and 34.5% of subjects from Brazil and Cambodia, respectively, versus none (0%) of the P. falciparum-infected subjects from Mali who have no exposure to P. vivax. IgG1 and IgG3 most frequently contributed to anti-PvVir14 responses. PvVir14 antibody levels correlated with those against other well-characterized sporozoite/liver (PvCSP) and blood stage (PvDBP-RII) antigens, which were recognized by 7.6% and 42% of Brazilians, respectively. Concerning the cellular immune profiling of Brazilian subjects, PvVir14 seroreactive individuals displayed significantly higher levels of circulating atypical (CD21- CD27-) B cells, raising the possibility that atypical B cells may be contribute to the PvVir14 antibody response. When analyzed at a single-cell level, the B cell receptor gene hIGHV3-23 was only seen in subjects with active P.vivax infection where it comprised 20% of V gene usage. Among T cells, CD4+ and CD8+ levels differed (lower and higher, respectively) between subjects with versus without antibodies to PvVir14, while NKT cell levels were higher in those without antibodies. Specific B cell subsets, anti-PvVir14 circulating antibodies, and NKT cell levels declined after treatment of P. vivax. This study provides the immunological characterization of PvVir14, a unique P. vivax protein, and possible association with acute host's immune responses, providing new information of specific host-parasite interaction. Trial registration: TrialClinicalTrials.gov Identifier: NCT00663546 & ClinicalTrials.gov NCT02334462.
Asunto(s)
Malaria Falciparum , Malaria Vivax , Humanos , Plasmodium vivax/genética , Proteínas Protozoarias/genética , Antígenos de Protozoos , Plasmodium falciparum , Anticuerpos Antiprotozoarios , Malaria Vivax/parasitología , Malaria Falciparum/epidemiología , Brasil/epidemiología , Familia , Inmunoglobulina G , Malí/epidemiologíaRESUMEN
Five species of Plasmodium cause malaria in humans and two of them, P. vivax and P. falciparum, pose the greatest threat. Rapid antigen detection tests (RADT) have been used for many years to diagnose and distinguish malaria caused by these two parasites. P. falciparum malaria can single-handedly be diagnosed using an RADT, which detects the unique P. falciparum specific histidine-rich protein 2 (HRP2). Unfortunately, there is no RADT that can single-handedly diagnose P. vivax malaria because no specific marker of this parasite has yet been described. Here, we report the discovery of a unique P. vivax protein (Vir14, NCBI Reference Sequence: XP_001612449.1) that has no sequence similarity with proteins of P. falciparum and no significant similarities with proteins of other species of Plasmodium. We propose that this protein could be an outstanding candidate molecule for the development of a promising RADT that can single-handedly and specifically diagnose P. vivax malaria.
RESUMEN
Canine visceral leishmaniasis (CVL) is a serious zoonotic disease in Brazil and Southern Europe. CVL is primarily caused by Leishmania infantum and its diagnosis relies largely on detection of parasites in bone marrow or lymph node aspirates by microscopic observation of the parasites in stained smears, parasite culture, or polymerase chain reaction (PCR). Serological tests exist but they do not distinguish active disease from simple exposure to parasite antigens. Here, we have assessed the utility of a new monoclonal antibody--based antigen (protein) detection test for the diagnosis of CVL. The test was positive in 70% of beagle dogs experimentally infected with L. infantum. In contrast, culture of the parasites from bone marrow aspirates was positive in only 40% of the infected animals. These preliminary results suggest that this antigen detection test, which we have recently described for the diagnosis of human VL, has the potential to be a useful diagnostic tool for CVL.
Asunto(s)
Antígenos de Protozoos/sangre , Enfermedades de los Perros/parasitología , Leishmaniasis Visceral/veterinaria , Animales , Antígenos de Protozoos/orina , Enfermedades de los Perros/diagnóstico , Perros , Leishmaniasis Visceral/diagnóstico , Sensibilidad y EspecificidadRESUMEN
This review describes and appraises a novel protein-based antigen detection test for visceral leishmaniasis (VL). The test detects in patient's urine six proteins from Leishmania infantum (chagasi) and Leishmania donovani, the etiological agents of VL. The gold standard test for VL is microscopic observation of the parasites in aspirates from spleen, liver, or bone marrow (and lymph node for dogs). Culture of the parasites or detection of their DNA in these aspirates are also commonly used. Serological tests are available but they cannot distinguish patients with active VL from either healthy subjects exposed to the parasites or from subjects who had a successful VL treatment. An antigen detection test based on the agglutination of anti-leishmania carbohydrates antibody coated latex beads has been described. However, the results obtained with this carbohydrate-based test have been conflicting. Using mass spectrometry, we discovered six L. infantum/L. donovani proteins excreted in the urine of VL patients and used them as markers for the development of a robust mAb-based antigen (protein) detection test. The test is assembled in a multiplexed format to simultaneously detect all six markers. Its initial clinical validation showed a sensitivity of 93% and specificity of 100% for VL diagnosis.
RESUMEN
The development of an accurate protein-based antigen detection assay for diagnosis of active visceral leishmaniasis (VL) would represent a major clinical advance. VL is a serious and fatal disease caused by the parasites Leishmania infantum and Leishmania donovani. The gold standard confirmatory diagnostic test for VL is the demonstration of parasites or their DNA from aspirates from spleen, lymph node, and bone marrow or from blood buffy coats. Here we describe the production and use of monoclonal antibodies (mAbs) for the development of a sensitive and specific antigen detection capture ELISA for VL diagnosis. This test simultaneously detects six leishmania protein biomarkers that we have previously described (Li-isd1, Li-txn1, Li-ntf2, Ld-mao1, Ld-ppi1 and Ld-mad1). The initial clinical validation of this new mAb-based multiplexed capture ELISA showed a sensitivity of ≥93%. The test was negative with 35 urine samples from healthy control subjects as well as with 30 patients with confirmed non-VL tropical diseases (cutaneous leishmaniasis, n = 6; Chagas disease, n = 6; schistosomiasis, n = 6; and tuberculosis, n = 12). These results strongly support the possible utility of this mAb-based multiplexed capture ELISA as a promising diagnostic test for active VL as well as for monitoring the treatment efficacy of this disease. The test is ready for upscaling and validation for clinical use.
Asunto(s)
Anticuerpos Monoclonales/inmunología , Antígenos de Protozoos/orina , Leishmania donovani/química , Leishmania infantum/química , Leishmaniasis Visceral/diagnóstico , Urinálisis/métodos , Orina/química , Adolescente , Adulto , Anciano , Anticuerpos Antiprotozoarios/inmunología , Antígenos de Protozoos/inmunología , Biomarcadores/orina , Niño , Preescolar , Ensayo de Inmunoadsorción Enzimática/métodos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Sensibilidad y Especificidad , Adulto JovenRESUMEN
Objetivo Analisar o conhecimento e a adesão ao Papanicolau de mulheres que frequentam Unidades Básicas de Saúde. Métodos Um questionário composto de questões pré-codifi cadas e abertas foi aplicado às usuárias de duas Unidades Básicas de Saúde da cidade de São José do Rio Preto, São Paulo, localizadas em bairros com perfi l socioeconômico distinto. Os dados foram analisados estatisticamente pelo programa Statistical Package for the Social Sciences.Resultados Após a análise de 99 questionários respondidos, ficou evidente um nível de conhecimento melhor sobre o exame de Papanicolau das residentes do bairro com melhores condições socioeconômicas e das mulheres mais jovens. Ficou evidente que muitas fazem esse exame sem saber o devido objetivo desse procedimento. A vergonha e a falta de tempo foram relatadas como motivos relevantes para não realizar o exame. Conclusão A falta de informação sobre o exame de Papanicolau das mulheres com mais de 60 anos e menor nível socioeconômico ficou evidente neste estudo e pode ser considerada um dos aspectos mais relevantes à não adesão à prevenção do câncer do colo de útero. Dessa maneira, ações de saúde alternativas deveriam ser adotadas pelas Unidades Básicas de Saúde para melhor orientar a população e, assim, aumentar a adesão a esse exame.
Objective To analyze the knowledge and adhesion to the Papanicolaou smear test of women attending Basic Health Units. Methods A questionnaire composed of pre-coded and open questions was applied to users of two Basic Health Units of the city of São José do Rio Preto, São Paulo, located in districts with different socioeconomic profiles. The data were statistically analyzed by the Statistical Package for the Social Sciences program. Results After the analysis of 99 questionnaires answered, a better level of knowledge about the Pap smear was found among the residents of the better socioeconomic neighborhood and the younger women. It has become evident that many take this test without knowing the proper purpose of this procedure. Shame and lack of time were reported as relevant reasons for not doing the test. Conclusion The lack of information on the Papanicolaou smear of women over 60 years of age and lower socioeconomic level was evident in this study and may be considered one of the most relevant aspects to non-adherence to cervical cancer prevention. In this way, alternative health actions should be adopted by the Basic Health Units to better guide the population and thus increase adherence to this examination.
Asunto(s)
Displasia del Cuello del Útero , Examen Ginecologíco , Prueba de PapanicolaouRESUMEN
Visceral leishmaniasis (VL) is a serious and fatal disease caused by the parasites Leishmania infantum and Leishmania donovani The gold standard diagnostic test for VL is the demonstration of parasites or their DNA in spleen, lymph node, or bone marrow aspirates. Serological tests exist but cannot distinguish active VL from either prior exposure to the parasites or previously treated VL disease. Using mass spectroscopy, we have previously identified three L. infantum protein biomarkers (Li-isd1, Li-txn1, and Li-ntf2) in the urine of VL patients and developed a sensitive and specific urine-based antigen detection assay for the diagnosis of VL that occurs in Brazil (where VL is caused by L. infantum). However, unpublished observations from our laboratory at DetectoGen showed that these biomarkers were detected in only 55% to 60% of VL patients from India and Kenya, where the disease is caused by L. donovani Here, we report the discovery and characterization of two new biomarkers of L. donovani (Ld-mao1 and Ld-ppi1) present in the urine of VL patients from these two countries. Capture enzyme-linked immunosorbent assays using specific rabbit IgG and chicken IgY were developed, and the assays had sensitivities of 44.4% and 28.8% for the detection of Ld-mao1 and Ld-ppi1, respectively. In contrast, a multiplexed assay designed to simultaneously detect all five leishmanial biomarkers markedly increased the assay sensitivity to 82.2%. These results validate the utility of leishmanial protein biomarkers found in the urine of VL patients as powerful tools for the development of an accurate diagnostic test for this disease.
Asunto(s)
Ensayos Analíticos de Alto Rendimiento/métodos , Leishmaniasis Visceral/diagnóstico , Leishmaniasis Visceral/orina , Proteínas Protozoarias/orina , Adolescente , Adulto , Anciano , Anticuerpos Antiprotozoarios , Biomarcadores/orina , Brasil , Niño , Preescolar , Ensayo de Inmunoadsorción Enzimática/métodos , Femenino , Humanos , India , Kenia , Leishmania donovani/aislamiento & purificación , Leishmania infantum/aislamiento & purificación , Leishmaniasis Visceral/parasitología , Masculino , Espectrometría de Masas , Persona de Mediana Edad , Sensibilidad y Especificidad , Adulto JovenRESUMEN
We have recently developed a sensitive and specific urine-based antigen detection ELISA for the diagnosis of visceral leishmaniasis (VL). This assay used rabbit IgG and chicken IgY polyclonal antibodies specific for the Leishmania infantum proteins iron superoxide dismutase 1 (Li-isd1), tryparedoxin1 (Li-txn1) and nuclear transport factor 2 (Li-ntf2). However, polyclonal antibodies have limitations for upscaling and continuous supply. To circumvent these hurdles, we began to develop immortalized monoclonal antibodies. We opted for recombinant camelid VHHs because the technology for their production is well established and they do not have Fc, hence providing less ELISA background noise. We report here an assay development using VHHs specific for Li-isd1 and Li-ntf2. This new assay was specific and had analytical sensitivity of 15-45 pg/mL of urine. The clinical sensitivity was comparable to that obtained with the ELISA assembled with conventional rabbit and chicken antibodies to detect these two antigens. Therefore, similar to our former studies with conventional antibodies, the future inclusion of VHH specific for Li-txn1 and/or other antigens should further increase the sensitivity of the assay. These results confirm that immortalized VHHs can replace conventional antibodies for the development of an accurate and reproducible antigen detection diagnostic test for VL.
Asunto(s)
Anticuerpos Antiprotozoarios/inmunología , Pruebas Inmunológicas/métodos , Leishmaniasis Visceral/diagnóstico , Anticuerpos de Dominio Único/inmunología , Adolescente , Adulto , Animales , Anticuerpos Antiprotozoarios/sangre , Antígenos de Protozoos/sangre , Antígenos de Protozoos/inmunología , Camélidos del Nuevo Mundo , Pollos , Niño , Preescolar , Femenino , Humanos , Lactante , Leishmania infantum/inmunología , Leishmaniasis Visceral/sangre , Leishmaniasis Visceral/parasitología , Masculino , Persona de Mediana Edad , Conejos , Sensibilidad y Especificidad , Anticuerpos de Dominio Único/sangre , Adulto JovenRESUMEN
Identification of pathogen-specific biomarkers present in patients' serum or urine samples can be a useful diagnostic approach. In efforts to discover Mycobacterium tuberculosis (Mtb) biomarkers we identified by mass spectroscopy a unique 21-mer Mtb peptide sequence (VVLGLTVPGGVELLPGVALPR) present in the urines of TB patients from Zimbabwe. This peptide has 100% sequence homology with the protein TBCG_03312 from the C strain of Mtb (a clinical isolate identified in New York, NY, USA) and 95% sequence homology with Mtb oxidoreductase (MRGA423_21210) from the clinical isolate MTB423 (identified in Kerala, India). Alignment of the genes coding for these proteins show an insertion point mutation relative to Rv3368c of the reference H37Rv strain, which generated a unique C-terminus with no sequence homology with any other described protein. Phylogenetic analysis utilizing public sequence data shows that the insertion mutation is apparently a rare event. However, sera from TB patients from distinct geographical areas of the world (Peru, Vietnam, and South Africa) contain antibodies that recognize a purified recombinant C-terminus of the protein, thus suggesting a wider distribution of isolates that produce this protein.
Asunto(s)
Proteínas Bacterianas/orina , Mycobacterium tuberculosis/química , Proteómica , Tuberculosis/orina , Secuencia de Aminoácidos , Anticuerpos Antibacterianos/sangre , Proteínas Bacterianas/química , Proteínas Bacterianas/genética , Proteínas Bacterianas/inmunología , Biomarcadores/química , Biomarcadores/orina , Análisis por Conglomerados , Humanos , Mycobacterium tuberculosis/inmunología , Oxidorreductasas/química , Oxidorreductasas/genética , Oxidorreductasas/inmunología , Oxidorreductasas/orina , Fragmentos de Péptidos/química , Fragmentos de Péptidos/genética , Fragmentos de Péptidos/inmunología , Fragmentos de Péptidos/orina , Tuberculosis/sangre , Tuberculosis/diagnósticoRESUMEN
Visceral leishmaniasis (VL) is a serious and fatal disease. Therapeutic drugs are toxic and non-sterilizing. The etiological agents Leishmania infantum and Leishmania donovani cause active and asymptomatic diseases. Effective drugs to treat VL exist but unfortunately, post-treatment relapses are common. Little is known why drugs are non-sterilizing or how these intracellular pathogens can escape treatment. Here, using a murine model of VL we found that CD271+/Sca1+ bone marrow mesenchymal stem cells (BM-MSCs) are readily infected in vitro and in vivo by L. infantum. Because BM-MSCs express potent drug efflux pumps, e.g., ABCG2 it is possible that this unique intracellular infectious niche could allow L. infantum to escape anti-parasite drugs.
Asunto(s)
Leishmania infantum/patogenicidad , Leishmaniasis Visceral/patología , Leishmaniasis Visceral/parasitología , Células Madre Mesenquimatosas/parasitología , Animales , Modelos Animales de Enfermedad , Humanos , Leishmaniasis Visceral/metabolismo , Masculino , Células Madre Mesenquimatosas/metabolismo , Células Madre Mesenquimatosas/patología , Ratones , Ratones Endogámicos C57BL , Receptores de Factor de Crecimiento Nervioso/metabolismo , Nicho de Células MadreRESUMEN
Visceral leishmaniasis (VL) diagnosis is routinely performed by invasive liver, spleen, bone marrow, or lymph node biopsies, followed by microscopic identification of the parasites. Conventional serological tests cannot distinguish active disease from asymptomatic VL or from cured infection. Here, we report the initial validation of an enzyme-linked immunosorbent assay (ELISA) assembled to detect the Leishmania infantum/donovani antigens iron superoxide dismutase 1 (Li-isd1), tryparedoxin 1 (Li-trx1), and nuclear transport factor 2 (Li-ntf2) as a tool to monitor therapeutic efficacy of VL. The assembled ELISA detected the antigens in the urine samples from seven VL patients before initiation of therapy. Importantly, the antigens were no longer detected in all patients after completion of the treatment. These preliminary observations point to a promising tool to follow treatment efficacy of VL.
Asunto(s)
Anticuerpos Antiprotozoarios/inmunología , Antígenos de Protozoos/orina , Leishmania infantum/inmunología , Leishmaniasis Visceral/diagnóstico , Proteínas Protozoarias/orina , Anfotericina B/administración & dosificación , Animales , Biomarcadores/orina , Pollos , Ácido Desoxicólico/administración & dosificación , Combinación de Medicamentos , Ensayo de Inmunoadsorción Enzimática/veterinaria , Humanos , Leishmania infantum/efectos de los fármacos , Leishmania infantum/aislamiento & purificación , Leishmaniasis Visceral/tratamiento farmacológico , Proteínas de Transporte Nucleocitoplasmático/inmunología , Proteínas de Transporte Nucleocitoplasmático/orina , Proteínas Protozoarias/inmunología , Conejos , Proteínas Recombinantes , Sensibilidad y Especificidad , Superóxido Dismutasa/inmunología , Superóxido Dismutasa/orina , Tiorredoxinas/inmunología , Tiorredoxinas/orina , Resultado del TratamientoAsunto(s)
Antituberculosos/uso terapéutico , Tuberculosis Latente/tratamiento farmacológico , Tuberculosis Latente/microbiología , Mycobacterium tuberculosis/efectos de los fármacos , Tuberculosis Pulmonar/tratamiento farmacológico , Tuberculosis Pulmonar/microbiología , Animales , Modelos Animales de Enfermedad , Genotipo , Humanos , Tuberculosis Latente/diagnóstico , Tuberculosis Latente/inmunología , Ratones SCID , Mycobacterium tuberculosis/genética , Mycobacterium tuberculosis/inmunología , Mycobacterium tuberculosis/patogenicidad , Fenotipo , Tuberculosis Pulmonar/diagnóstico , Tuberculosis Pulmonar/inmunología , VirulenciaRESUMEN
In areas were human visceral leishmaniasis (VL) is endemic, the domestic dog is the main parasite reservoir in the infectious cycle of Leishmania infantum. Development of prophylactic strategies to lower the parasite burden in dogs would reduce sand fly transmission thus lowering the incidence of zoonotic VL. Here we demonstrate that vaccination of dogs with a recombinant 14kDa polypeptide of L. infantum nuclear transport factor 2 (Li-ntf2) mixed with adjuvant BpMPLA-SE resulted in the production of specific anti-Li-ntf2 IgG antibodies as well as IFN-γ release by the animals' peripheral blood mononuclear cells stimulated with the antigen. In addition, immunization with this single and small 14kDa poplypeptide resulted in protracted progression of the infection of the animals after challenging with a high dose of virulent L. infantum. Five months after challenge the parasite load was lower in the bone marrow of immunized dogs compared to non-immunized animals. The antibody response to K39, a marker of active VL, at ten months after challenge was strong and significantly higher in the control dogs than in vaccinated animals. At the study termination vaccinated animals showed significantly more liver granulomas and lymphoid hyperplasia than non-vaccinated animals, which are both histological markers of resistance to infection. Together, these results indicate that the 14kDa polypeptide is an attractive protective molecule that can be easily incorporated in a leishmanial polyprotein vaccine candidate to augment/complement the overall protective efficacy of the final product.
RESUMEN
The pioneer human oral commensal bacterium Streptococcus mitis has unique biologic features that make it an attractive mucosal vaccine or therapeutic delivery vector. S. mitis is safe as a natural persistent colonizer of the mouth, throat and nasopharynx and the oral commensal bacterium is capable of inducing mucosal antibody responses. A recombinant S. mitis (rS. mitis) that stably expresses HIV envelope protein was generated and tested in the germ-free mouse model to evaluate the potential usefulness of this vector as a mucosal vaccine against HIV. Oral vaccination led to the efficient and persistent bacterial colonization of the mouth and the induction of both salivary and systemic antibody responses. Interestingly, persistently colonized animals developed antigen-specific systemic T cell tolerance. Based on these findings we propose the use of rS. mitis vaccine vector for the induction of mucosal antibodies that will prevent the penetration of the mucosa by pathogens such as HIV. Moreover, the first demonstration of rS. mitis having the ability to elicit T cell tolerance suggest the potential use of rS. mitis as an immunotherapeutic vector to treat inflammatory, allergic and autoimmune diseases.
Asunto(s)
Vacunas contra el SIDA/inmunología , Vectores Genéticos/genética , Tolerancia Inmunológica , Mucosa Bucal/inmunología , Streptococcus mitis/genética , Linfocitos T/inmunología , Vacunas Sintéticas/inmunología , Vacunas contra el SIDA/genética , Animales , Anticuerpos Antivirales/inmunología , Femenino , Vectores Genéticos/administración & dosificación , Proteína gp120 de Envoltorio del VIH/genética , Proteína gp120 de Envoltorio del VIH/inmunología , Ratones , Ratones Endogámicos BALB C , Streptococcus mitis/inmunología , Vacunas Sintéticas/genéticaRESUMEN
The incidence of opportunistic non-tuberculous mycobacteria (NTM) infections has increased considerably in the past decades causing an array of infections, including respiratory and soft-tissue infections. NTM are ubiquitous and can be found in numerous environments, including households and water plants. However, NTM have not been reported to be associated with the healthy human oral microbiome. Since the oral cavity and upper respiratory track are the main ports of entry of microorganisms into the human body, elucidating NTM diversity and prevalence will assist in the assessment of the potential risks of infection elicited by these opportunistic pathogens. Here, we report the identification of a 'non-tuberculous mycobacteriome' in healthy individuals. We employed a modified DNA extraction procedure in conjunction with mycobacterial-specific primers to screen niches in the oral cavity (buccal mucosa and dental plaque) and upper respiratory tract (nostrils and oropharynx) of 10 healthy subjects. A total of 50 prevalent operational taxonomic units sequenced on MiSeq (Illumina) using 16S rRNA V3-V4 region were detected across all screened niches, showing the presence of diverse NTM communities. NTM DNA was detected in the nostrils of all 10 subjects, in buccal mucosa of 8 subjects, in the oropharynx of 7 subjects, and in the dental plaques of 5 subjects. Results from quantitative PCR showed each individual harbored 10(3)-10(4) predicted NTM per each screened niche. The modification of standard DNA isolation methods to increase sensitivity toward mycobacterial species represents an important step to advance the knowledge of the oral as well as the overall human microbiome. These findings clearly reveal for the first time that healthy individuals harbor a 'non-tuberculous mycobacteriome' in their oral cavity and upper respiratory tract and may have important implications in our understanding of infections caused by NTM.
RESUMEN
The development of vaccine approaches that induce mucosal and systemic immune responses is critical for the effective prevention of several infections. Here, we report on the use of the abundant human oral commensal bacterium Streptococcus mitis as a delivery vehicle for mucosal immunization. Using homologous recombination we generated a stable rS. mitis expressing a Mycobacterium tuberculosis protein (Ag85b). Oral administration of rS. mitis in gnotobiotic piglets resulted in efficient oral colonization and production of oral and systemic anti-Ag85b specific IgA and IgG antibodies. These results support that the commensal S. mitis is potentially a useful vector for mucosal vaccination.
Asunto(s)
Vacunas Bacterianas/inmunología , Absorción por la Mucosa Oral/inmunología , Streptococcus mitis/inmunología , Vacunación/métodos , Administración Oral , Animales , Proteínas Bacterianas/genética , Vectores Genéticos/inmunología , Membrana Mucosa , Mycobacterium tuberculosis , Streptococcus mitis/genética , Porcinos/inmunologíaRESUMEN
During tuberculosis (TB), some Mycobacterium tuberculosis bacilli persist in the presence of an active immunity and antibiotics that are used to treat the disease. Herein, by using the Cornell model of TB persistence, we further explored our recent finding that suggested that M. tuberculosis can escape therapy by residing in the bone marrow (BM) mesenchymal stem cells. We initially showed that M. tuberculosis rapidly disseminates to the mouse BM after aerosol exposure and maintained a stable burden for at least 220 days. In contrast, in the lungs, the M. tuberculosis burden peaked at 28 days and subsequently declined approximately 10-fold. More important, treatment of the mice with the antibiotics rifampicin and isoniazid, as expected, resulted in effective clearance of M. tuberculosis from the lungs and spleen. In contrast, M. tuberculosis persisted, albeit at low numbers, in the BM of antibiotic-treated mice. Moreover, most viable M. tuberculosis was recovered from the bone marrow CD271(+)CD45(-)-enriched cell fraction, and only few viable bacteria could be isolated from the CD271(-)CD45(+) cell fraction. These results clearly show that BM mesenchymal stem cells provide an antibiotic-protective niche for M. tuberculosis and suggest that unraveling the mechanisms underlying this phenomenon will enhance our understanding of M. tuberculosis persistence in treated TB patients.
Asunto(s)
Antibacterianos/uso terapéutico , Células de la Médula Ósea/microbiología , Células Madre Mesenquimatosas/microbiología , Mycobacterium tuberculosis/patogenicidad , Adapaleno , Animales , Antituberculosos/uso terapéutico , Médula Ósea/microbiología , Modelos Animales de Enfermedad , Farmacorresistencia Bacteriana , Femenino , Humanos , Isoniazida/uso terapéutico , Antígenos Comunes de Leucocito/metabolismo , Pulmón/microbiología , Ratones , Ratones Endogámicos C57BL , Mycobacterium tuberculosis/efectos de los fármacos , Naftalenos/metabolismo , Rifampin/uso terapéutico , Bazo/microbiología , Tuberculosis/tratamiento farmacológicoRESUMEN
Accruing data strongly support the possible role of CD8+ T cells in immunity against tuberculosis (TB). Multivalent vaccines against Mycobacterium tuberculosis (Mtb) that incorporate CD8+ T cell antigens with those that elicit CD4+ T cells are therefore highly desirable. To screen for potential CD8+ T cell antigens that are produced by Mtb during infection, we isolated pathogen-derived peptides that bound to MHC Class I molecules expressed in adherent splenocytes obtained from Mtb-infected mice. Mass spectroscopy analysis revealed the following four nonamer peptides that had 100% homology with Mtb proteins: DGYVGAPAH (MT_0401), TTMPLFAD (MT_1164), RSGAATPVR (MT_2160.1) and LAAVVGVVL (MT_0078). The gene MT_0401 codes the protein 5'-phosphoribosylglycinamide transformylase 2 and the other three genes code for hypothetical proteins with unknown function. The NCBI/Blast analysis showed that among the four peptides DGYVGAPAH had the highest maximum alignment score and lowest E value (number of alignments expected by chance). Therefore, we assessed whether MT_0401 expressed in two genetic vaccine formulations was capable of stimulating CD8+ T cell response that is specific to DGYVGAPAH peptide. When mice were immunized with a recombinant plasmid DNA and an E1/E3-deleted Adenovirus 5 expressing MT0401 protein, using both homologous and heterologous prime-boost protocols, they developed strong DGYVGAPAH-specific CD8+ T cell response as well as antibody and CD4+ specific T cell response to the full length MT0401 protein. Equally important was the observation that mice infected with Mtb developed DGYVGAPAH-specific CD8+ T cell responses in both spleen and lungs. These results demonstrate that Mtb antigens that are processed and presented via MHC Class I machinery can be readily identified by the described approach and may be useful candidate antigens to stimulate specific CD8+ T cell responses in vaccine development programs.